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Biology

Downregulation of RNA Editing Enzyme
ADAR1 Reduces the Oncogenic Potential of
Triple-Negative Breast Cancer
Emily Bross
Mentor: Jason Weber
Adenosine deaminase acting on RNA (ADAR1) is a RNA-editing enzyme that converts
adenosine into inosine, resulting in alterations of the RNA sequence and subsequent
downstream effects. It has been shown to be over-expressed in a variety of cancers
including breast cancer but its exact role in tumorigenesis remains unclear. To better
understand the effects of ADAR1 on breast cancer tumorigenesis, we generated shRNAcontaining lentiviruses to knock-down the expression of ADAR1 in human breast cancer
cell lines. We performed Western blot analysis to verify the successful knock-down of
ADAR1 protein. We conducted focus formation assay to test the effect of ADAR1 knockdown on human breast cancer cell lines’ proliferative abilities. We also performed scratch
assay to test the metastatic potential of the same cell lines.
ADAR1 expression was successfully downregulated in all of the human breast cancer
cell lines we tested. Interestingly, downregulation of ADAR1 reduced proliferation
of triple-negative breast cancer (TNBC) cell lines while having little effect on the
proliferation of non-TNBC cell lines. Scratch assay also revealed the downregulation
of ADAR1 inhibited the migratory abilities of TNBC cell lines. These results suggest
that ADAR1 is a key player in the oncogenic nature of TNBC. We are in the process of
performing in vivo mouse studies to verify our findings from the cell culture system and
to develop an animal model for future development of potential innovative treatment
options. Further investigation promises to illuminate novel targeted therapeutic
approaches currently lacking in the treatment of TNBC.
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